WO2023011147A1 - 人源化高中和活性抗新型冠状病毒单克隆抗体及应用 - Google Patents

人源化高中和活性抗新型冠状病毒单克隆抗体及应用 Download PDF

Info

Publication number
WO2023011147A1
WO2023011147A1 PCT/CN2022/106147 CN2022106147W WO2023011147A1 WO 2023011147 A1 WO2023011147 A1 WO 2023011147A1 CN 2022106147 W CN2022106147 W CN 2022106147W WO 2023011147 A1 WO2023011147 A1 WO 2023011147A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
ser
seq
leu
val
Prior art date
Application number
PCT/CN2022/106147
Other languages
English (en)
French (fr)
Inventor
邵一鸣
李丹
王铮
靳昌忠
苏俊威
任莉
Original Assignee
中国疾病预防控制中心性病艾滋病预防控制中心
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国疾病预防控制中心性病艾滋病预防控制中心 filed Critical 中国疾病预防控制中心性病艾滋病预防控制中心
Publication of WO2023011147A1 publication Critical patent/WO2023011147A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention discloses a polypeptide, more specifically, the invention discloses an antibody.
  • SARS-Cov-2 (also known as 2019-nCov) is a type of positive-strand RNA virus belonging to the ß genus of the coronavirus family, which encodes four structural proteins: spike (S), envelope(E), membrane (M), and nucleocapsid (N), 16 nonstructural proteins, and 5-8 auxiliary proteins.
  • SARS Cov-2 uses the S protein on the surface of the virus and the host cell receptor-angiotensin-converting enzyme II (ACE2) to enter cells.
  • ACE2 host cell receptor-angiotensin-converting enzyme II
  • S protein is divided into two functional units according to protein structure and function, namely S1 and S2 protein subunits.
  • S1 can be divided into NTD (N-terminal domain) and RBD (Receptor binding site).
  • the RBD region is about 240 amino acids long and mainly binds to host cell receptors. S2 plays a role in the fusion of virus and cell membranes. According to existing reports, neutralizing antibodies mainly act on the RBD region, and the antibody binds to RBD to prevent the combination of RBD and ACE2, thereby preventing the virus from infecting cells.
  • the purpose of the present invention is to provide a group of anti-new coronavirus monoclonal antibodies with high neutralization activity, and on this basis, to provide the application of the high neutralization activity anti-new coronavirus monoclonal antibodies in the preparation of drugs for the treatment of new coronavirus disease.
  • the present invention firstly provides a humanized broad-spectrum high neutralizing active anti-new coronavirus monoclonal antibody, the CDR1, CDR2 and CDR3 of the heavy chain variable region of the antibody and the light chain variable region of the antibody
  • the amino acid sequences of CDR1, CDR2 and CDR3 are as follows:
  • amino acid sequences of the variable region of the antibody heavy chain and the variable region of the light chain are as follows:
  • amino acid sequence of the heavy chain constant region of the antibody is shown in SEQ ID NO.13
  • amino acid sequence of the light chain constant region is shown in SEQ ID NO.15.
  • the present invention provides a polynucleotide encoding the above-mentioned humanized broad-spectrum high neutralizing active anti-new coronavirus monoclonal antibody, a polynucleotide encoding the variable region of the heavy chain of the antibody, and a polynucleotide encoding the light antibody of the antibody.
  • the sequences of the polynucleotides of the variable regions of the chains are as follows:
  • sequence of the polynucleotide encoding the constant region of the heavy chain of the antibody is shown in SEQ ID NO.14
  • sequence of the polynucleotide encoding the constant region of the light chain is shown in SEQ ID NO.16.
  • the present invention also provides a vector for expressing the above-mentioned humanized high neutralizing activity anti-new coronavirus monoclonal antibody, which contains the above-mentioned polynucleotide encoding the variable region of the heavy chain of the antibody and encoding the above-mentioned
  • the carrier can be a eukaryotic expression vector routinely used in genetic engineering, in a specific embodiment of the present invention, the carrier is IgH (heavy chain expression vector) , Ig ⁇ ( ⁇ light chain expression vector) (see Tiller et al.
  • the present invention provides a host cell expressing the above-mentioned humanized high neutralizing activity anti-new coronavirus monoclonal antibody, said host cell containing the above-mentioned vector.
  • the host cell may be a eukaryotic host cell routinely used in genetic engineering.
  • the host cell is a 293F cell.
  • the present invention provides the application of the above-mentioned humanized high neutralizing active anti-new coronavirus monoclonal antibody in the preparation of new coronavirus disease treatment and/or preventive drugs, and the antibody or antibody composition can be used to develop clinical therapeutic drugs, Targeted drugs, SARS-COV-2 recombinant proteins and subunit vaccines.
  • the application may be a composition application containing at least two antibodies.
  • the three kinds of antibodies provided by the present invention not only have high neutralizing activity, but also have broad-spectrum, and have strong neutralizing ability against various variant strains of the new coronavirus in the world, so the application contains at least two or more of the present invention
  • the antibody composition can more effectively enhance the broad-spectrum neutralization ability of multiple mutant strains of the new coronavirus, so the antibody composition containing the present invention is used in the development of clinical therapeutic drugs, targeted drugs, SARS-COV-2 recombinant proteins and Subunit vaccines have broad application prospects, and specific applications can include the combined application of SW-C11 and WJQ-G10, the combined application of SW-C11 and WJQ-C11, the combined application of WJQ-G10 and WJQ-C11, and the combined application of SW- Combination application of 3 antibody strains of C11, WJQ-G10 and WJQ-C11.
  • the present invention provides the application of the above-mentioned humanized high neutralizing active anti-novel coronavirus monoclonal antibody in the preparation of novel coronavirus detection reagents.
  • the humanized high neutralizing activity anti-new coronavirus monoclonal antibody provided by the present invention is obtained by screening a single B cell flow cytometry-antibody gene amplification paired expression technology, has a unique CDR region, and can be specific to SARS-COV-2 Sexually combined and can effectively neutralize many current international epidemic viruses (Wuhan strain, British mutant strain B.1.1.7, South African mutant strain B.1.351, Brazilian mutant strain P.1, Indian mutant strain B.1.617.1 and B .1.617.2), which has a significant broad-spectrum neutralization ability against many different representative strains of new coronaviruses worldwide.
  • the antibody provided by the invention and the composition containing the two antibodies can be used to prepare COVID-19 emergency preventive and/or therapeutic drugs, which have the characteristics of full humanization, high expression, and good stability, and are suitable for industrialization.
  • the antibody can also be used to prepare SARS-COV-2 virus detection reagents, to detect virus antigens and to find effective neutralizing antigen epitopes.
  • Figure 1 The titer detection results of biotinylated RBD protein, in which A. magnetic bead method to detect RBD biotinylation efficiency; B. ELISA method to detect biotinylation efficiency;
  • Figure 2 Schematic diagram of flow cytometric sorting of RBD-specific B cells
  • Example 1 Synthesis, expression, biotinylation and staining of the novel coronavirus RBD probe
  • the two probe plasmids were respectively transfected into 293F cells for expression. After 5-6 days, the culture medium was centrifuged to collect the cell supernatant, and the antigenic protein was purified through a nickel column.
  • the probe protein was biotinylated using the BirA 500 Biotin Protein Ligase Kit (BirA500, Avidity).
  • the biotinylation activity of the two probes was detected by enzyme-linked immunosorbent assay (Enzyme-linked Immunosorbent Assay, ELISA).
  • ELISA enzyme-linked Immunosorbent Assay
  • Dilute the new crown antigen with PBS to 2 ⁇ g/mL add it to a 96-well ELISA plate, 100 ⁇ L per well, place it at 4 °C overnight, wash 3 times with PBST (PBS containing 0.05% Tween 20) the next day; add 370 ⁇ L per well Block with blocking solution (PBS containing 2% milk and 5% FBS) at room temperature for 1 hour, wash with PBST (PBS containing 0.05% Tween 20) 3 times; add 100 ⁇ L of blocking solution to each well, and then add to each well in the first row 25 ⁇ L of diluted biotin-labeled probe protein (the storage concentration of biotinylated probe protein is 50 ⁇ g/mL, diluted 5 times in blocking solution before use), after mixing
  • Figure 1 shows the titer detection results of biotinylated RBD protein, where A is the detection efficiency of RBD biotinylation by magnetic bead method, and lanes 1-2 are streptavidin magnetic beads capturing biotin from RBD protein after 10 ⁇ g of biotin.
  • Successfully primed RBD lane 3 is 10 ⁇ g biotinylated RBD, and lane 4 is the molecular weight marker; it can be seen from Figure 1A that the biotinylation efficiency of RBD exceeds 50%;
  • B is the biotinylation efficiency detected by ELISA method, the probe
  • the final concentration (end titer) was 0.0032 ⁇ g/mL. It can be seen from the results that the biotinylation of RBD was successful.
  • the RBD-Avi probe protein is fluorescently labeled with PE (phycoerythrin) for use in single cell flow cytometry.
  • Embodiment 2 screening and identification of anti-SARS-COV-2 humanized monoclonal antibody
  • Centrifuge at 1500 rpm for 10 minutes discard the supernatant, suspend the cells with the residual solution, add 10 mL R10, mix well, take 50 ⁇ l for cell counting, and centrifuge at 1500 rpm for 10 minutes; adjust the cell concentration: discard the supernatant, and use residual Suspend the cells in liquid, use R10 medium to adjust the concentration, and place 2.5 ⁇ 106 cells/well in a 96-well U-shaped plate;
  • Vivid (UV) working solution 1:1000 diluted with PBS, mix well
  • mix well and incubate on ice for 20 minutes in the dark;
  • RT-PCR reaction program setting react at 42°C for 10 minutes, react at 25°C for 10 minutes, react at 50°C for 50 minutes, react at 94°C for 5 minutes, and store at 4°C.
  • the primer sequences for the first round of PCR amplification are as follows
  • the amplified target fragments of the primers used in the first round of PCR amplification are shown in Table 5.
  • the first round of PCR reaction program is shown in Table 6.
  • the amplified target fragments of the primers used for the second round of PCR amplification are shown in Table 9.
  • the second round of PCR products were detected by electrophoresis, and the heavy and light chain products were directly sequenced; the sequencing results were analyzed using the antibody family gene database (http://www.imgt.org/IMGT_vquest/vquest), and enzyme-cleaved antibodies were designed and synthesized.
  • the antibody variable region sequence of the site (heavy chain: 5'-Age I, 3'-Sal I; Kappa chain: 5'-Age I, 3'-BsiW I; Lambda chain: 5'-Age I, 3' -Xho I), a total of 97 paired clones of heavy chain and light chain were obtained.
  • the synthesized gene was cleaved with the corresponding enzyme and recovered by gel electrophoresis again.
  • T4 DNA ligase the variable region gene was combined with the corresponding vector IgH (heavy chain expression vector), Ig ⁇ ( ⁇ light chain expression vector), Ig ⁇ ( ⁇ light chain expression vector) (see Tiller et al. Efficient generation of monoclonal Antibodies from single human B cells by single cell RT-PCR and expression vector cloning, J Immunol Methods. 2008 January 1; 329(1-2): 112–124., the present invention incorporates this prior art document into the description of the present invention by reference) connecting 16 °C water bath overnight for transformation.
  • Solution A add 500 ⁇ g antibody heavy chain DNA and 500 ⁇ g antibody light chain DNA to 25ml opti-MEM
  • solution B add 5ml PEI transfection reagent to 25ml opti-MEM, let stand for 5 minutes.
  • the antibody was purified using a Protein A affinity column (product of GE health).
  • the antibody concentration was determined using a NanoDrop2000 ultra-micro spectrophotometer (product of Thermo Company), and placed at 4°C for detection. In this step, 61 antibodies were expressed from 97 antibody light/heavy chain pairs (antibody amount>10 ⁇ g, antibody concentration>10 ⁇ g/mL).
  • Embodiment 3 Antibody is to the neutralizing activity determination of SARS-COV-2 pseudovirus
  • a 96-well plate In a 96-well plate, add 100 ⁇ L of serially diluted antibody dilution solution to each well, then dilute the pseudovirus to 1.3 ⁇ 10 4 TCID50/mL with DMEM complete medium, and add 50 ⁇ L to each well of columns 3-11 to make the pseudovirus The amount added is 650 TCID50/well.
  • the above 96-well plate was placed in a cell culture incubator (37° C., 5% CO 2 ) and incubated for 1 hour.
  • the incubation time When the incubation time reaches half an hour, take out the prepared Vero cells, aspirate and discard the medium, add PBS buffer to wash the cells, discard the PBS, add trypsin-EDTA to digest and centrifuge, add complete medium to resuspend the cells, and count the cells. Dilute the cell suspension to 2 ⁇ 10 cells/mL. Incubate for 1 hour, add 100 ⁇ L of cells to each well of the 96-well plate, so that the number of cells per well is 2 ⁇ 10 4 . Gently shake the 96-well plate back and forth, so that the cells are evenly dispersed in the wells, put the 96-well plate in a cell culture incubator, and incubate for 28 hours at 37°C and 5% CO 2 .
  • amino acid and nucleotide sequences of the three antibody strains are as follows:
  • the nucleotide sequence of the heavy chain variable region of antibody SW-C11 is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.1, wherein the CDR1,
  • the amino acid sequences of CDR2 and CDR3 are respectively shown in amino acids 26-33, 51-57 and 96-106 of SEQ ID NO.1;
  • the nucleotide sequence of the light chain variable region is shown in SEQ ID NO.4
  • the light chain variable region The amino acid sequence of the chain variable region is shown in SEQ ID NO.3, wherein the amino acid sequences of CDR1, CDR2 and CDR3 of the light chain variable region are as shown in SEQ ID NO.3 27-32, 50-52, and 89, respectively. -97 amino acid.
  • the nucleotide sequence of the heavy chain variable region of antibody WJQ-G10 is shown in SEQ ID NO.6, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.5, wherein the CDR1,
  • the amino acid sequences of CDR2 and CDR3 are respectively shown in amino acids 26-33, 51-57 and 96-106 of SEQ ID NO.5;
  • the nucleotide sequence of the light chain variable region is shown in SEQ ID NO.8, and the light chain variable region
  • the amino acid sequence of the chain variable region is shown in SEQ ID NO.7, wherein the amino acid sequences of CDR1, CDR2 and CDR3 of the light chain variable region are as shown in SEQ ID NO.7 27-32, 50-52, 89 -97 amino acid.
  • the nucleotide sequence of the heavy chain variable region of antibody WJQ-C11 is shown in SEQ ID NO.10, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.9, wherein the CDR1, The amino acid sequences of CDR2 and CDR3 are respectively shown in amino acids 26-33, 51-58 and 97-109 of SEQ ID NO.9; the nucleotide sequence of the light chain variable region is shown in SEQ ID NO.12, and the light chain variable region
  • the amino acid sequence of the chain variable region is shown in SEQ ID NO.11, wherein the amino acid sequences of CDR1, CDR2 and CDR3 of the light chain variable region are shown in the 27-32, 50-52, and 89 of SEQ ID NO.11, respectively. -97 amino acid.
  • the above three antibody strains share the same heavy chain constant region and light chain constant region.
  • the nucleotide sequence of the heavy chain constant region is as SEQ As shown in ID NO.14, the amino acid sequence of the constant region of the heavy chain is shown in SEQ ID NO.13, and the light chain is of the Kappa type, and the nucleotide sequence of the constant region is shown in SEQ ID NO.16, The amino acid sequence of the heavy chain constant region is shown in SEQ ID NO.15.
  • Embodiment 4 Neutralization experiment of antibody to live virus
  • Vero-E6 cells were seeded in a 48-well plate at a cell number of 25,000/well one day in advance, and cultured in MEM medium containing 10% FBS and double antibodies.
  • Antibody configuration Dilute the antibody with MEM medium containing 5% FBS and double antibody. Calculate according to the final volume of 500 ⁇ L/well in the 48-well plate and 3 replicate wells for each concentration, prepare 750 ⁇ L (250 ⁇ L/well) of antibodies at each concentration, and prepare antibodies at twice the actual concentration. Starting from the highest concentration, perform a doubling dilution according to a certain multiple (such as 3 times). At the same time, set up corresponding positive and negative controls. Add the prepared antibody to the 48-well plate and bring it into the P3 laboratory.
  • SW-C11 and WJQ-G10 have good neutralizing effects on Wuhan, Brazil, South Africa, and Indian mutant strains; SW-C11 neutralizes The Wuhan and Indian strains had the strongest ability, with IC50 reaching 0.0173 ⁇ g/mL and 0.0056 ⁇ g/mL, respectively.
  • the antigen-binding abilities of the three antibodies were determined by ELISA method.
  • the RBD protein (NC_045512) was diluted to 2 ⁇ g/ml with PBS, and 100 ⁇ l per well was coated on a 96-well ELISA plate (Corning Costar Company), overnight at 4°C. Wash the plate 5 times with PBS-T solution (0.05% Tween-20); add 250 ⁇ l blocking solution (PBS, 2% BSA+5% skimmed milk powder) to each well to block at room temperature for 1 hour. Wash the plate 3 times with PBS-T.
  • the initial concentration of the antibody was 10 ⁇ g/ml, and the blocking solution was used for 5-fold serial dilution, and 100 ⁇ l samples were added to the ELISA plate, and incubated at 37°C for 1 hour. Wash the plate 5 times with PBS-T. Add 100 ⁇ l of horseradish-enzyme-labeled goat anti-human IgG (H+L) (Beijing Zhongshan Jinqiao Biotechnology Co., Ltd.) diluted with blocking solution 1:5000 to each well, and incubate at 37°C for 1 hour. Wash the plate 5 times with PBS-T.
  • the biosensor probes were dipped into wells containing serially diluted antibodies (500 nM, 250 nM, 125 nM, 62.5 nM, 31.25 nM, 15.625 nM, and 7.8125 nM) and bound for 120 s, followed by 300 s. seconds dissociation step. KD values were calculated using the 1:1 binding model in Data Analysis Software 9.0.
  • the affinity constant of WJQ-G10 is (1.37 ⁇ 10 -9 ⁇ 3.53 ⁇ 10 -11 )M
  • the affinity constant of WJQ-C11 is (5.29 ⁇ 10 -9 ⁇ 6.16 ⁇ 10 -11 )M
  • SW-C11 The affinity constant KD of RBD ⁇ 10 -12 M (10 -12 M is the lower limit of affinity determined by BLI technique), the results are shown in Figure 4- Figure 6. It was shown that these 3 antibodies have extremely strong affinity for RBD.
  • the invention provides an anti-new coronavirus monoclonal antibody and application thereof.
  • the antibody is easy for industrial production and drug preparation, and has industrial applicability.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

本发明抗体基因扩增配对表达技术筛选获得，具有独特的CDR区域，能特异性与SARS-COV-2结合并且可以有效中和目前多株国际流行病毒，其IC50大部分在1μg/mL以下。还公开了所述抗体制备新型冠状病毒病治疗或预防药物中的应用以及在制备新型冠状病毒检测试剂中的应用。所述抗体可以用于COVID-19紧急预防和/或治疗，具有全人源，高表达，稳定性好的特点，适合产业化。

Description

人源化高中和活性抗新型冠状病毒单克隆抗体及应用 技术领域
本发明公开了一种多肽，更具体地，本发明公开一种抗体。
 背景技术
SARS-Cov-2（也称为2019-nCov） 属于正链 RNA 病毒的一种，属于冠状病毒家族的 ß 属，其编码四种结构蛋白：spike (S), envelope(E), membrane (M), 和nucleocapsid (N)、16 种非结构蛋白，及 5-8 种辅助蛋白质。SARS Cov-2利用病毒表面的 S 蛋白与宿主细胞受体-血管紧张素转换酶 II（ACE2）进入细胞。S 蛋白根据蛋白结构功能又被分为两个功能单位，即 S1 和 S2 蛋白亚基。S1 可分为 NTD（N-terminal domain）和 RBD（Receptor binding site），RBD 区域长约 240 个氨基酸，主要与宿主细胞受体结合，S2 在病毒和细胞膜融合起作用。根据已有的报导，中和抗体主要作用于 RBD 区域，抗体结合于 RBD，阻碍 RBD 与ACE2 的结合，从而阻止病毒感染细胞。
 技术问题
目前国内外均有新冠中和抗体的分离研究报道，采用单细胞分选和抗体基因组深度测序方法，一批针对 RBD 的人源化单克隆抗体被分离出来，如 1F11、2F6、CA1、CB6、BD-368-2 等，这些抗体展现出了较强的体外中和活性（IC50<1μg/ml），在表达 ACE2 的转基因小鼠动物体内也展现出了较好的治疗效果，可以显著降低小鼠肺部的病毒载量。但 SARS-Cov-2 处于不断变异中，一旦感染了中和表位发生变异的病毒，则已有的中和抗体将不再具有中和作用。事实上，已经有英国B.1.1.7突变株（N501Y、D614G）、巴西突变株P.1(N501Y、 E484k、 k417T、D614G)、南非突变株B.1.351（K417N、E484K、N501Y、D614G）,印度突变株B.1.617（L452R、E484Q、D614G）相继出现，该三毒株对部分中和抗体或疫苗诱导出的抗体不敏感，且由于其较强的传播能力被世界卫生组织列为VOC（Variants of concern, 受关注的变异病毒）。因此，有必要分离出更多的强效中和抗体作为备选，将这些针对不同表位的中和抗体进行各种配伍，探索鸡尾酒疗法，可以更有效地避免病毒发生免疫逃逸，目前科学界尚无已报道的类似广谱抗体以及抗体组合物。本发明的目的就是提供一组具有高中和活性抗新型冠状病毒单克隆抗体，在此基础上并提供所述高中和活性抗新型冠状病毒单克隆抗体在制备新冠病毒病治疗药物中的应用。
 技术解决方案
基于上述发明目的，本发明首先提供了一种人源化广谱高中和活性抗新型冠状病毒单克隆抗体，所述抗体的重链可变区的CDR1、CDR2和CDR3以及轻链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如下所示：
（1）SEQ ID NO.1的第26-33、51-57 和96-106位氨基酸以及SEQ ID NO.3的第27-32、50-52、89-97位氨基酸；或者
（2）SEQ ID NO.5的第26-33、51-57和96-106位氨基酸以及SEQ ID NO.7的第27-32、50-52和89-97位氨基酸；或者
（3）SEQ ID NO.9的第26-33、51-58和97-109位氨基酸以及SEQ ID NO.11的第27-32、50-52和89-97位氨基酸。
在一个优选的实施方案中，所述抗体重链的可变区以及轻链的可变区的氨基酸序列分别如下所示：
（1）SEQ ID NO.1以及SEQ ID NO.3；在本发明中，具有该重链的可变区以及轻链的可变区氨基酸序列的一个具体技术方案的抗体被命名为“SW-C11”，或者
（2）SEQ ID NO.5以及SEQ ID NO.7；在本发明中，具有该重链的可变区以及轻链的可变区氨基酸序列的一个具体技术方案的抗体被命名为“WJQ-G10”，或者
（3）SEQ ID NO.9以及SEQ ID NO.11，在本发明中，具有该重链的可变区以及轻链的可变区氨基酸序列的一个具体技术方案的抗体被命名为“WJQ-C11”。
在一个更为优选的实施方案中，所述抗体重链恒定区的氨基酸序列如SEQ ID NO.13所示，所述轻链恒定区的氨基酸序列如SEQ ID NO.15所示。
其次，本发明提供了一种编码上述人源化广谱高中和活性抗新型冠状病毒单克隆抗体的多核苷酸，编码所述抗体重链的可变区的多核苷酸以及编码所述抗体轻链的可变区的多核苷酸的序列分别如下所示：
（1）SEQ ID NO.2以及SEQ ID NO.4；或者
（2）SEQ ID NO.6以及SEQ ID NO.8；或者
（3）SEQ ID NO.10以及SEQ ID NO.12。
在一个优选的实施方案中，编码抗体重链恒定区的多核苷酸的序列如SEQ ID NO.14所示，所述轻链恒定区的多核苷酸的序列如SEQ ID NO.16所示。
第三，本发明还提供了一种表达上述人源化高中和活性抗新型冠状病毒单克隆抗体的载体，所述载体含有上述编码所述抗体重链的可变区的多核苷酸以及编码所述抗体轻链的可变区的多核苷酸，所述载体可以是基因工程中常规使用的真核表达载体，在本发明的一个具体实施方案中，所述载体为 IgH（重链表达载体）、Igκ（κ轻链表达载体）（具体参见Tiller et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning, J Immunol Methods. 2008 January 1; 329(1-2): 112–124.，本发明通过引用将该现有技术文件并入到本发明的说明书中）。
第四，本发明提供了一种表达上述人源化高中和活性抗新型冠状病毒单克隆抗体的宿主细胞，所述宿主细胞含有上述的载体。
所述宿主细胞可以为基因工程中常规使用的真核宿主细胞，在本发明的一个具体实施方案中，所述宿主细胞为293F细胞。
第五，本发明提供了上述人源化高中和活性抗新型冠状病毒单克隆抗体在制备新型冠状病毒病治疗和/或预防药物中的应用，所述抗体或者抗体组合物可以开发临床治疗药物，靶向药物、SARS-COV-2重组蛋白及亚单位疫苗。
在一个优选的实施方案中，所述应用可以为含有至少两种抗体的组合物应用。本发明提供的3种抗体不仅具有高中和活性，而且还具有广谱性，对目前世界范围内的多种新冠病毒变异株都具有较强的中和能力，因此应用含有本发明至少两种以上的抗体组合物能够更有效地提升对新冠病毒多个变异株广谱的中和能力，因此含有本发明的抗体组合物形式在开发临床治疗药物，靶向药物、SARS-COV-2重组蛋白及亚单位疫苗具有广阔的应用前景，具体的应用可以包括SW-C11与WJQ-G10的组合应用，SW-C11与WJQ-C11的组合应用，WJQ-G10 与WJQ-C11的组合应用，以及SW-C11、WJQ-G10和WJQ-C11的3株抗体的组合应用。
最后，本发明提供了上述人源化高中和活性抗新型冠状病毒单克隆抗体在制备新型冠状病毒检测试剂中的应用。
 有益效果
本发明提供的人源化高中和活性抗新型冠状病毒单克隆抗体通过单个B细胞流式分选-抗体基因扩增配对表达技术筛选获得，具有独特的CDR区域，能与SARS-COV-2特异性结合并且可以有效中和目前多株国际流行病毒（wuhan株，英国突变株B.1.1.7，南非突变株B.1.351，巴西突变株P.1，印度突变株B.1.617.1和B.1.617.2），对世界范围内多个不同的新型冠状病毒代表株具有显著的广谱中和能力。因此本发明提供的抗体以及含有两种抗体的组合物可以用于制备COVID-19紧急预防和/或治疗药物，具有全人源化，高表达，稳定性好的特点，适合产业化。此外，该抗体还可用于制备SARS-COV-2病毒检测试剂，用于检测病毒抗原以及用于发现有效中和抗原表位。
 附图说明
图1. 生物素化RBD蛋白的效价检测结果图，其中 A.磁珠法检测RBD生物素化效率；B.ELISA法检测生物素化效率；
图2. 流式分选RBD特异性B细胞示意图；
图3. 抗体针对RBD结合能力的ELISA结果图；
图4. 采用BLI技术检测SW-C11抗体的抗体-抗原亲和力结果图；
图5. 采用BLI技术检测WJQ-G10抗体的抗体-抗原亲和力结果图；
图6. 采用BLI技术检测WJQ-C11抗体的抗体-抗原亲和力结果图。
 本发明的实施方式
下面结合具体实施例来进一步描述本发明，本发明的优点和特点将会随着描述而更为清楚。但这些实施例仅是范例性的，并不对本发明的权利要求所限定的保护范围构成任何限制。
实施例1：新冠病毒RBD探针的合成、表达和生物素化及染色
1.1依据 Genbank公布的数据（NC_045512），合成携带6×His-Avi（His-His-His-His-His-His-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-Asp-Ile-Thr-Asn-Trp-Leu-Trp-Tyr-ILe-Lys-Lys-Lys）标签的RBD全长基因序列。
1.2 经EcoRI和 EcoRV双酶切后重新连接入真核表达载体pDRVI1.0（发明人构建并保存），挑选克隆后经测序无误。
1.3将两探针质粒分别转染293F细胞进行表达，5-6天后离心培养液收取细胞上清，过镍柱纯化抗原蛋白。
1.4使用BirA 500生物素蛋白连接酶试剂盒（BirA500，Avidity）对探针蛋白进行生物素化。
将1mg分子探针蛋白溶解于0.7mL PBS缓冲液中，分别加入0.1mL 10×缓冲液A、0.1mL 10×缓冲液B，再加入4μL BirA 500 酶，混匀，30℃孵育30分钟;将混合物转移至10K浓缩管中，加10mL PBS，离心4000g 15min至剩余体积0.5mL，重复这一操作5次;收集浓缩后的蛋白并测定浓度，存放至-80℃冰箱。
1.5 检测分子探针生物素化活性
采用60微升链霉素标记的琼脂糖+10微克蛋白 +500微升PBS置室温振荡器中摇30min，短暂离心，用1ml的PBS洗3次，最后一次尽量将液体吸弃干净，最后剩下大概30微升的琼脂糖，同时准备30微升的2×SDS凝胶加样缓冲液（100 mM pH6.8 Tris-HCl、 4%SDS、0.2% 溴酚兰、20%甘油、200 mM β-巯基乙醇）上样缓冲液，将琼脂糖和混合缓冲液1:1混在一起，吸取20微升置于100℃,5-10min然后进行 SDS-PAGE电泳;电泳结束后加适量考马斯亮蓝染色1小时后置于振荡器中脱色后观察电泳条带的深浅，判定生物素标记的效率，至少在50%以上可考虑进行荧光标记。
采用酶联免疫吸附试验（Enzyme-linked Immunosorbent Assay，ELISA）检测两探针的生物素化活性。用PBS将新冠抗原稀释至2μg/mL，加入96孔ELISA板中，每孔100μL，置于4℃过夜，次日用PBST(含0.05% 吐温20的PBS) 洗3次；每孔加入370μL封闭液（含2% 牛奶和5% FBS的PBS）室温封闭1小时，用PBST(含0.05% 吐温20的PBS) 洗3次；向每孔加入100μL封闭液，第一行每孔再加入25μL稀释好的生物素标记的探针蛋白（生物素化的探针蛋白贮存浓度为50μg/mL，使用前5倍稀释于封闭液中），混匀后从第一行每孔吸出25μL加入到第二行中，混匀后吸出25μL加入到第三行中，依次直至最后一行吸出25μL丢掉（每行之间形成五倍稀释梯度），37℃孵育1小时，用PBST(含0.05% 吐温20的PBS) 洗5次；将辣根过氧化物酶标记的链霉亲和素（Sigma KPL HRP-SA）1000倍稀释于含有0.05% 吐温20的封闭液中，每孔加100μL，37℃孵育1小时，用PBST洗5次板；每孔加入100μL底物，室温孵育20分钟后每孔加入50μL硫酸终止液立即终止反应，在酶标仪上读数保存。图1为生物素化RBD蛋白的效价检测结果，其中A为磁珠法检测RBD生物素化效率，泳道1-2为链霉亲和素磁珠从10μg生物素后的RBD蛋白中捕获生物素化成功的RBD，泳道3为10 μg生物素化RBD，泳道4为分子量标志；由图1A可以看出，RBD生物素化效率超过50%；B为ELISA法检测生物素化效率，探针的终末浓度（end titer）为0.0032μg/mL。由结果可以看出，RBD的生物素化成功。
1.6生物素化的探针蛋白进行荧光标记
RBD-Avi探针蛋白用PE（藻红蛋白）进行荧光标记，以备单细胞流式分选时使用。
实施例2:抗SARS-COV-2人源化单克隆抗体的筛选和鉴定
2.1配制细胞裂解液：每孔20μl细胞裂解液，包含0.5μl 去RNA酶，5μl 5×First Strand 缓冲液，1.25μL 0.1M DTT，0.0625μl Igepal，13.25μl水，盖好封板膜，4°C冰箱放置待用。
2.2 样本准备：
（1）新冠感染后康复者PBMCs细胞复苏：将冻存细胞管从液氮拿出后，迅速置于37℃水浴中，待融化至有冰芯时拿出，在生物安全柜中打开，缓慢滴入R10+ Benzonase培养基（1支细胞使用5 mL R10+ Benzonase培养基）。1500 rpm离心10分钟，弃去上清，用残液悬起细胞，加入 10 mL R10，混匀，取50 μl进行细胞计数，1500 rpm离心10分钟；调整细胞浓度：弃去上清，用残液悬起细胞，使用R10培养基调整浓度，向96孔U型板中2.5×10 6个/孔；
（2）配制 2 mM 的 EDTA/PBS 溶液，下文用 E-PBS 表示；
（3）将96孔细胞板置于离心机内，4 ℃，2000 rpm 离心 3 分钟，弃去上清（生物安全柜内操作，纸巾高压放台内）；
（4）每孔加入50 μl Vivid工作液（配制 Vivid（UV）工作液：1:1000用PBS稀释，混匀），混匀，避光冰上孵育20分钟；
（5）每孔加入150 μl E-PBS，4 ℃，2000 rpm离心3分钟；
（6）弃去上清，加入50 μl胞外抗体混合液（2μl Anti-CD3-Alexflour 700，1.5μl Anti-CD8-Pacific Blue，1.5μl Anti-CD14-Pacific Blue，1μl Anti-CD19-PECy7，2.5μl Anti-CD20-ECD，2μl Anti-CD27-APCCy7，1μl Anti-IgG-FITC，1μl Anti-IgM-PECy5，5μl Anti-RBD-PE，不足用E-PBS补齐），混匀，避光冰上孵育60分钟；
（7）每孔加入150 μL E-PBS，4 ℃，2000 rpm离心3分钟，弃去上清；
（8）每孔加入200 μL E-PBS，4 ℃，2000 rpm离心3分钟，弃去上清；
（9）每孔加入200 μL E-PBS，混匀，同一样本细胞悬液过滤到同一支流式管内，4 ℃避光保存供分选；
（10）单染管对照：设置1个未染色管对照（加入1滴补偿微球，200μl E-PBS）和10个单独染色管（每管加入补偿微球1滴，分别加入2μl Anti-CD3-Alexflour 700，1.5μl Anti-CD8-Pacific Blue，1.5μl Anti-CD14-Pacific Blue，1μl Anti-CD19-PECy7，2.5μl Anti-CD20-ECD，2μl Anti-CD27-APCCy7，1μl Anti-IgG-FITC，1μl Anti-IgM-PECy5，5μl Anti-RBD-PE，50μl UV工作液），混匀，避光冰上孵育20分钟后每孔加入150 μl E-PBS，4 ℃，2000 rpm离心3分钟，弃上清，200μl E-PBS重悬。
2.3 单个 B 细胞流式分选：选择CD3 -CD8 -CD14 -CD19 +CD20 +CD27 +IgG +IgM -RBD +的细胞进行分选，合计分选到56个细胞。首选圈定出单淋巴细胞群，再圈定出CD3 -CD8-CD14-的活细胞以排除T细胞和巨噬细胞，再圈出CD19 +CD20 +的B细胞，再圈定出CD27 +的记忆B细胞，再圈出IgG +IgM -的B细胞，最后圈出与探针RBD结合的记忆性B细胞。将这些B细胞每孔1个分选入含有以下裂解液体系的96孔板中（表1）。分选结束后，立刻用封口膜封好96孔板，在干冰上凝固，再转移入-80℃冰箱，过夜，第二天进行PCR操作。结果：流式分选的结果如图2所示。
表1. B细胞裂解液体系
Figure 513454dest_path_image001
2.4 利用RT-PCR技术扩增全人源抗体可变区基因
配置如表2所示RT-PCR反应体系，每孔加入6μl，进行RT-PCR反应
              表2. RT-PCR反应体系
Figure 481410dest_path_image002
RT-PCR反应程序设定：42℃反应10min，25℃反应10min，50℃反应50min，94℃反应5min，4度保存。
（1）进行两轮PCR反应，反应体系如下
第一轮PCR反应体系（表3）补充引物序列（表4）
表3. 第一轮PCR反应体系
Figure 577542dest_path_image003
表4. 第一轮PCR扩增用引物序列如下
Figure 289146dest_path_image004
Figure 685492dest_path_image005
 
第一轮PCR扩增用引物的扩增目的片段如表5所示。
表5. 第一轮PCR扩增用引物的扩增目的片段
Figure 824349dest_path_image006
第一轮PCR反应程序如表6所示。
表6. 第一轮PCR程序
Figure 407777dest_path_image007
 第一轮PCR反应结束后进行第二轮PCR反应，第二轮PCR反应体系如表7所示。
表7.第二轮PCR反应体系
Figure 316215dest_path_image008
第二轮PCR引物序列如表8所示。
表8.第二轮PCR引物序列
Figure 301489dest_path_image009
 第二轮PCR扩增用引物的扩增目的片段如表9所示。
表9. 第二轮PCR扩增用引物的扩增目的片段
Figure 611247dest_path_image010
第二轮PCR反应程序如表10所示。
表10.第二轮PCR程序
Figure 213130dest_path_image011
(2) 电泳、测序、家系分析
电泳检测二轮PCR产物，将重链和轻链产物直接测序；使用抗体家系基因数据库（http://www.imgt.org/IMGT_vquest/vquest）对测序结果进行分析，设计并合成带有酶切位点的抗体可变区序列（重链：5‘-Age I，3’-Sal I；Kappa链：5‘-Age I，3‘-BsiW I；Lambda链：5‘-Age I，3’-Xho I），共计获得97对重链和轻链配对克隆。
2.5单克隆抗体表达载体构建和质粒转化
将合成的基因用相应的酶进行酶切后再次凝胶电泳回收，使用T4 DNA连接酶将可变区基因与相应载体IgH（重链表达载体）、Igκ（κ轻链表达载体）、Igλ（λ轻链表达载体）（具体参见Tiller et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning, J Immunol Methods. 2008 January 1; 329(1-2): 112–124. ，本发明通过引用将该现有技术文件并入到本发明的说明书中）在16℃连接仪上连接16°C水浴过夜，转化。 将10μL 连接产物加入50μL DH5α感受态细胞中，振动摇匀，冰浴30分钟，42°C水浴热激45秒。离心管放入冰浴2分钟后，加入1mL无抗性的LB培养基，37°C，200rpm振荡培养1小时，4000rpm离心4分钟，将残留菌液涂布在抗性的LB平板上。37°C倒置培养14-16小时。挑取单克隆菌落接种到抗性的LB液体培养基中，37°C，200rpm振荡培养14-16小时后进行质粒提取（Omega公司的Plasmid Midi Kit）。
2.6 抗体表达和纯化
将293F细胞浓度调整为1.2×10 6个/ml，培养2小时。配置A液：25ml的opti-MEM加入500μg抗体重链DNA和500μg抗体轻链DNA，B液：25ml的opti-MEM中加入5ml的PEI转染试剂，静置5分钟。将A和B液混合，静置20分钟，逐滴加入1L的293F细胞中，边滴边摇匀，置于8%CO 2，37°C下，摇动培养5天。
利用Protein A亲和柱（GE health公司产品）纯化得到抗体。利用NanoDrop2000超微量分光光度计（Thermo公司产品）测定抗体浓度，4°C放置待检测。本步骤从97个抗体轻/重链配对中表达出61个抗体（抗体量>10μg, 抗体浓度>10μg/mL）。
实施例3 抗体对SARS-COV-2假病毒的中和活性测定
3.1 假病毒的包装：人工合成SARS-CoV-2(GenBank: MN908947)的S蛋白基因全长插入pcDNA3.1表达质粒，构建pcDNA-SARS-CoV2-S。带有突变的假病毒突变位点如表11所示，在S基因上引入。
表11. 假病毒突变位点
Figure 266536dest_path_image012
 将3×10 6（300万）个293T/17细胞接种于T75细胞培养瓶，5%CO 2 37℃培养20-24小时。使用Fugene 6 Transfection Reagent (Promega, Cat#E2691) 进行转染：将30ug质粒pcDNA-SARS-CoV2-S 转染T75培养瓶中的293T细胞，同时加入1.05×10 6 TCID50 的G*ΔG-VSV病毒感染293T，8小时后更换培养基。转染24小时后，收集培养上清并过滤获得SARS-CoV2 S蛋白的假病毒，-80℃冷冻保存。
3.2中和实验：
在一块96孔板中每孔加入100μL梯度稀释的抗体稀释液随后，用DMEM完全培养基将假病毒稀释至1.3×10 4 TCID50/mL，于第3-11列每孔加50 μL，使假病毒的加入量为650 TCID50/孔。将上述96孔板置于细胞培养箱中(37℃、5%CO 2)孵育1小时。当孵育时间至半小时，取出准备好的Vero细胞，吸弃培养基，加入PBS缓冲液清洗细胞，弃去PBS，加入胰酶-EDTA消化离心后，加入完全培养基重悬细胞，细胞计数。将细胞悬液稀释至2×10 5个/mL。孵育至1小时，向96孔板中每孔加100 μL细胞，使每孔细胞为2×10 4个。将96孔板前后左右轻轻晃动，使细胞在孔中分散均匀，将96孔板放入细胞培养箱中，37℃、5%CO 2培养 28 小时。从细胞培养箱中取出96孔板，用多道移液器从每个上样孔中吸弃150 μL上清，然后加入100 μL荧光素酶检测试剂，室温避光反应2分钟。反应结束后，于平板振荡器震荡混匀，放入多功能读板机中读取发光值。计算中和抑制率：根据中和抑制率结果，计算抗体的IC50。
Figure 106317dest_path_image013
从61个测试抗体中，我们筛选出3株针对新冠南非突变株、新冠巴西变异株、新冠英国变异株、新冠印度变异株、新冠武汉株假病毒均具备较强中和活性的广谱中和抗体，所述3株抗体的编号分别为SW-C11、WJQ-G10和WJQ-C11。3株抗体针对不同变异株假病毒的中和能力结果见表12。
表12.抗体针对不同变异株假病毒的中和能力（IC50，μg/mL）
Figure 993501dest_path_image014
通过对编码上述抗体株的克隆进行测序，所述3株抗体的氨基酸及核苷酸序列如下：
抗体SW-C11的重链可变区核苷酸序列如SEQ ID NO.2所示，重链可变区的氨基酸序列如SEQ ID NO.1所示，其中，重链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO.1的第26-33、51-57 和96-106位氨基酸所示；轻链可变区核苷酸序列如SEQ ID NO.4所示，轻链可变区的氨基酸序列如SEQ ID NO.3所示，其中，轻链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO.3的第27-32、50-52、89-97位氨基酸所示。
抗体WJQ-G10的重链可变区核苷酸序列如SEQ ID NO.6所示，重链可变区的氨基酸序列如SEQ ID NO.5所示，其中，重链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO.5的第26-33、51-57 和96-106位氨基酸所示；轻链可变区核苷酸序列如SEQ ID NO.8所示，轻链可变区的氨基酸序列如SEQ ID NO.7所示，其中，轻链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO.7的第27-32、50-52、89-97位氨基酸所示。
抗体WJQ-C11的重链可变区核苷酸序列如SEQ ID NO.10所示，重链可变区的氨基酸序列如SEQ ID NO.9所示，其中，重链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO.9的第26-33、51-58 和97-109位氨基酸所示；轻链可变区核苷酸序列如SEQ ID NO.12所示，轻链可变区的氨基酸序列如SEQ ID NO.11所示，其中，轻链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO.11的第27-32、50-52、89-97位氨基酸所示。
上述3株抗体享有相同的重链恒定区和轻链恒定区。所述重链恒定区的核苷酸序列如SEQ ID NO.14所示，所述重链恒定区的氨基酸序列如SEQ ID NO.13所示，所述轻链为Kappa型，其恒定区的核苷酸序列如SEQ ID NO.16所示，所述重链恒定区的氨基酸序列如SEQ ID NO.15所示.
     实施例4：抗体对活病毒的中和实验
提前1天将Vero-E6细胞按照25000/孔的细胞数接种于48孔板，用含10%FBS和双抗的MEM培养基培养。
抗体配置：用含5%FBS和双抗的MEM培养基稀释抗体。按照48孔板最终体积500μL/孔、每个浓度3个复孔计算，每个浓度的抗体配置750μL（250μL /孔），按照实际作用浓度的2倍配置抗体。从最高浓度开始，按照一定倍数（如3倍）进行倍比稀释。同时，设置相应的阳性和阴性对照。将配置好的抗体加入48孔板，带入P3实验室。
将新冠病毒储存液按照MOI=100比例用含5%FBS的MEM培养基稀释，按照1：1的体积比将病毒液（250μL /孔）加入配置好的抗体，37℃孵育3小时。将对数生长期的Vero-E6细胞板上清吸净，加入孵育好的抗体病毒混合液（500μL /孔），37℃培养7天。后续检测：观察细胞病变，推算中和百分比为50%的中和抗体的浓度，计为IC 50 。结果见表13。三种单抗均能有效中和武汉株活病毒和印度变异株活病毒，SW-C11和WJQ-G10对武汉、巴西、南非、印度变异株均有良好的中和作用；SW-C11中和武汉和印度毒株能力最强，IC50可分别达到0.0173μg/mL和0.0056μg/mL。
表13. 抗体针对活病毒的中和能力（IC50, μg/mL）
Figure 285942dest_path_image015
实施例5 抗体结合能力测定
通过ELISA方法测定所述3种抗体的抗原结合能力。将RBD蛋白（NC_045512）用PBS稀释至2μg/ml，每孔100μl包被96孔ELISA板（Corning Costar公司），4°C过夜。用PBS-T溶液（0.05%吐温-20）洗板5次；每孔加入250μl封闭液（PBS，2% BSA+5%脱脂奶粉）室温封闭1小时。PBS-T洗板3次。将抗体以10μg/ml为起始浓度，用封闭液进行5倍系列稀释，分别取100μl样本加入到ELISA板中，37°C孵育1小时。PBS-T洗板5次。每孔加入100μl用封闭液1：5000稀释后的辣根酶标记的山羊抗人IgG（H+L）（北京中杉金桥生物技术有限公司），37°C孵育1小时。PBS-T洗板5次。加入TMB显色溶液（北京金豪制药股份有限公司）100μl，室温避光显色20分钟。每孔加入50μl终止液（北京金豪制药股份有限公司）终止反应，酶标仪读取450nm波长的吸光度值（OD）结果如图3所示，图3中VRC01为抗HIV中和抗体，作为阴性对照。并计算End-titer值如下表14所示。
表14.中和抗体的End-titer值
Figure 674198dest_path_image016
实施例6 抗原-抗体亲和力动力学测定
利用Octet Red 96系统（Fortebio, USA）和链霉亲和素传感器，采用BLI技术对SW-C11、WJQ-G10、WJQ-C11与RBD蛋白（NC_045512）的亲和力进行检测，用PBST（含有0.02%吐温20和0.1%牛血清白蛋白的PBS）将SARS-Cov-2的生物素化RBD稀释至5μg/mL的浓度，然后固定到链霉亲和素生物传感器（Sartorius AG，Germany）上60秒。在用PBST进行60秒洗涤步骤后，将生物传感器探针浸入含有连续稀释抗体（500nM、250nM、125nM、62.5nM、31.25nM、15.625nM和7.8125nM）的孔中并结合120秒，然后进行300秒解离步骤。KD值采用数据分析软件9.0中的1:1结合模型计算。得出WJQ-G10的亲和力常数为(1.37×10 -9±3.53×10 -11)M，WJQ-C11的亲和力常数为（5.29×10 -9±6.16×10 -11)M, SW-C11与RBD的亲和力常数KD<10 -12M（10 -12M为BLI技术测定的亲和力下限），结果如图4-图6所示。显示这3个抗体针对RBD具有极强的亲和力。
工业实用性
本发明提供了一种抗新型冠状病毒单克隆抗体及其应用，所述抗体易于工业化生产和药物制备，具有工业实用性。
 序列表自由内容
序列表
<110>  中国疾病预防控制中心性病艾滋病预防控制中心
<120>  人源化高中和活性抗新型冠状病毒单克隆抗体及应用
<160>  16
<170>  SIPOSequenceListing 1.0
<210>  1
<211>  119
<212>  PRT
<213>  Homo sapiens
<400>  1
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly
1               5                   10                  15     
Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Phe Ile Val Ser Arg Asn
            20                  25                  30         
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Thr Gly Leu Glu Trp Val
        35                  40                  45             
Ser Val Ile Tyr Pro Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys
    50                  55                  60                 
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65                  70                  75                  80 
Gln Met Asp Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala
                85                  90                  95     
Arg Asp Tyr Gly Asp Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu
            100                 105                 110         
Val Thr Val Ser Ser Ala Ser
        115                
<210>  2
<211>  357
<212>  DNA
<213>  Homo sapiens
<400>  2
gaggtgcagc tggtggagtc tggaggaggc ttgatccagc ctggggggtc cctgagactc        60
tcctgtgcag cctctgagtt catcgtcagt agaaactaca tgagctgggt ccgccaggct       120
ccagggacgg ggctggagtg ggtctcagtt atttatcctg gaggcagcac attctacgca       180
gactccgtga agggccgatt caccatctcc agagacaatt ccaagaacac gctgtatctt       240
caaatggaca gcctgagagt cgaggacacg gccgtgtatt actgtgcgag agactacggt       300
gacttctatt ttgactactg gggccaggga accctggtca ccgtctcctc agcgtcg          357
<210>  3
<211>  109
<212>  PRT
<213>  Homo sapiens
<400>  3
Glu Ile Val Met Thr Gln Ser Pro Val Ser Leu Ser Val Ser Pro Gly
1               5                   10                  15     
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Gly Val Ala Ser Asn
            20                  25                  30         
Leu Ala Trp Tyr Gln Gln Lys Ala Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45             
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Thr Leu Gln Ser
65                  70                  75                  80 
Glu Asp Ser Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asp Arg Pro Arg
                85                  90                  95     
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr
            100                 105                
<210>  4
<211>  327
<212>  DNA
<213>  Homo sapiens
<400>  4
gaaatagtga tgacgcagtc tccagtctcc ctgtctgtgt ctccagggga aagagccacc        60
ctctcctgca gggccagtca gggtgttgcc agcaacttag cctggtacca gcagaaagct       120
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg aatcccagcc       180
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcac cctgcagtct       240
gaagattctg cagtttatta ctgccagcag tataatgata ggcccaggac ttttggccag       300
gggaccaagc tggagatcaa acgtacg                                           327
<210>  5
<211>  119
<212>  PRT
<213>  Homo sapiens
<400>  5
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Glu
1               5                   10                  15     
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn
            20                  25                  30         
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45              
Ser Val Ile Tyr Ala Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys
    50                  55                  60                 
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65                  70                  75                  80 
Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Ile Tyr Tyr Cys Ala
                85                  90                  95     
Arg Asp Leu Ser Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr
            100                 105                 110        
Val Thr Val Ser Ser Ala Ser
        115                
<210>  6
<211>  357
<212>  DNA
<213>  Homo sapiens
<400>  6
gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggggagtc cctgagactc        60
tcctgtgcag cctctggatt aaccgtcagt agcaactaca tgagttgggt ccgccaggct       120
ccagggaagg ggctggagtg ggtctcagtt atttatgccg gtggtagcac attctacgca       180
gactccgtga agggccgatt caccatctcc agagacaatt ccaagaatac gctgtatctt       240
caaatgaaca gcctgagagc tgaggatatg gctatttatt actgtgcgag agatctcagc       300
tactacggta tggacgtctg gggccaaggg accacggtca ccgtctcctc agcgtcg          357
<210>  7
<211>  109
<212>  PRT
<213>  Homo sapiens
<400>  7
Asp Ile Gln Leu Thr Gln Phe Pro Phe Ser Leu Ser Ala Ser Val Gly
1               5                   10                  15     
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Thr Tyr
            20                  25                  30         
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala Pro Lys Leu Leu Ile
        35                  40                  45             
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80 
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Leu Leu Asn Ser Tyr Pro Val
                85                  90                  95     
His Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr
            100                 105                
<210>  8
<211>  327
<212>  DNA
<213>  Homo sapiens
<400>  8
gacatccagt tgacccagtt tccattctcc ctgtctgcat ctgtaggaga cagagtcacc        60
atcacttgcc gggccagtca gggcattagc acttatttag cctggtatca gcaaaaacca       120
gggagagccc ctaagctcct gatctatgct gcatccactt tgcaaagtgg ggtcccatcg       180
aggttcagcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct       240
gaagattttg caacttatta ctgtcaactg cttaatagtt accctgtaca ctttggccag       300
gggaccaagc tggagatcaa acgtacg                                           327
<210>  9
<211>  122
<212>  PRT
<213>  Homo sapiens
<400>  9
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15     
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Thr Tyr
            20                  25                  30         
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45             
Ser Tyr Ile His Asn Ser Gly Asn Pro Val Tyr Tyr Ala Asp Ser Val
    50                  55                  60                 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Glu Asn Ser Leu Tyr
65                  70                  75                  80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys
                85                  90                  95     
Ala Arg Ala Leu Arg Tyr Ser Thr Ser Trp Tyr Asp Tyr Trp Gly Gln
            100                 105                 110        
Gly Thr Leu Val Thr Val Ser Ser Ala Ser
        115                 120        
<210>  10
<211>  366
<212>  DNA
<213>  Homo sapiens
<400>  10
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggagggtc cctgagactc        60
tcctgtgcag cctctggatt cgccttcagt acttatgaga tgaactgggt ccgccaggct       120
ccagggaagg ggctggagtg ggtttcatac attcataata gtggtaatcc cgtatactac       180
gcagactctg tgaagggccg attcaccatc tccagagaca acgccgagaa ctcactatat       240
ctgcaaatga acagcctgag agccgaggac acggctattt attactgtgc gagagcctta       300
cgttacagca ccagctggta tgactactgg ggccagggaa ccctggtcac cgtctcctca       360
gcgtcg                                                                  366
<210>  11
<211>  109
<212>  PRT
<213>  Homo sapiens
<400>  11
Glu Ile Val Leu Thr Gln Ser Pro Val Ser Leu Ser Leu Ser Pro Gly
1               5                   10                  15     
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
            20                  25                  30         
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Phe Ile
        35                  40                  45              
Tyr Asp Ala Ser Lys Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                 
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80 
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Arg
                85                  90                  95     
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
            100                 105                
<210>  12
<211>  327
<212>  DNA
<213>  Homo sapiens
<400>  12
gaaattgtgt tgacacagtc cccagtctcc ctgtctttgt ccccagggga aagagccacc        60
ctctcctgca gggccagtca gagtgttagc agctacttag cctggtacca acagaaacct       120
ggccaggctc ccaggctctt catttatgat gcatccaaga gggccactgg catcccagcc       180
aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag cctagagcct       240
gaagattttg cagtttatta ctgtcagcag cgtagcaact ggcctcgaac gttcggccaa       300
gggaccaagg tggaaatcaa acgtacg                                           327
<210>  13
<211>  328
<212>  PRT
<213>  Homo sapiens
<400>  13
Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr
1               5                   10                  15     
Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro
            20                  25                  30         
Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
        35                  40                  45             
His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser
    50                  55                  60                 
Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile
65                  70                  75                  80 
Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val
                85                  90                  95     
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
            100                 105                 110        
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
        115                 120                 125            
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
    130                 135                 140                
Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
145                 150                 155                 160
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
                165                 170                 175    
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
            180                 185                 190        
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
        195                 200                 205            
Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
    210                 215                 220                
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
225                 230                 235                 240
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
                245                 250                 255    
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
            260                 265                 270         
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
        275                 280                 285            
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
    290                 295                 300                 
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
305                 310                 315                 320
Ser Leu Ser Leu Ser Pro Gly Lys
                325            
<210>  14
<211>  984
<212>  DNA
<213>  Homo sapiens
<400>  14
accaagggcc catcggtctt ccccctggca ccctcctcca agagcacctc tgggggcaca        60
gcggccctgg gctgcctggt caaggactac ttccccgaac ccgtgacggt gtcgtggaac       120
tcaggcgccc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc       180
tactccctca gcagcgtggt gaccgtgccc tccagcagct tgggcaccca gacctacatc       240
tgcaacgtga atcacaagcc cagcaacacc aaggtggaca agaaagttga gcccaaatct       300
tgtgacaaaa ctcacacatg cccaccgtgc ccagcacctg aactcctggg gggaccgtca       360
gtcttcctct tccccccaaa acccaaggac accctcatga tctcccggac ccctgaggtc       420
acatgcgtgg tggtggacgt gagccacgaa gaccctgagg tcaagttcaa ctggtacgtg       480
gacggcgtgg aggtgcataa tgccaagaca aagccgcggg aggagcagta caacagcacg       540
taccgtgtgg tcagcgtcct caccgtcctg caccaggact ggctgaatgg caaggagtac       600
aagtgcaagg tctccaacaa agccctccca gcccccatcg agaaaaccat ctccaaagcc       660
aaagggcagc cccgagaacc acaggtgtac accctgcccc catcccggga tgagctgacc       720
aagaaccagg tcagcctgac ctgcctggtc aaaggcttct atcccagcga catcgccgtg       780
gagtgggaga gcaatgggca gccggagaac aactacaaga ccacgcctcc cgtgctggac       840
tccgacggct ccttcttcct ctacagcaag ctcaccgtgg acaagagcag gtggcagcag       900
gggaacgtct tctcatgctc cgtgatgcat gaggctctgc acaaccacta cacgcagaag       960
agcctctccc tgtctccggg taaa                                         984
<210>  15
<211>  105
<212>  PRT
<213>  Homo sapiens
<400>  15
Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu
1               5                   10                  15      
Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro
            20                  25                  30         
Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly
        35                  40                  45              
Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr
    50                  55                  60                 
Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His
65                  70                  75                  80 
Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val
                85                  90                  95     
Thr Lys Ser Phe Asn Arg Gly Glu Cys
            100                 105
<210>  16
<211>  315
<212>  DNA
<213>  Homo sapiens
<400>  16
gtggctgcac catctgtctt catcttcccg ccatctgatg agcagttgaa atctggaact        60
gcctctgttg tgtgcctgct gaataacttc taccccagag aagccaaagt gcagtggaag       120
gtggacaacg ccctgcagag cggaaacagc caggaaagcg tgacagagca ggattccaag       180
gattccacat acagcctgag cagcacactg acactgtcca aggccgacta cgagaagcac       240
aaggtgtacg cctgcgaagt gacacaccag ggactgtcct cccctgtgac aaagagcttc       300
aacagaggag aatgc                                               315

Claims (10)

  1. 一种人源化高中和活性抗新型冠状病毒单克隆抗体及应用，其特征在于，所述抗体的重链可变区的CDR1、CDR2和CDR3以及轻链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO.1的第26-33、51-57 和96-106位氨基酸以及SEQ ID NO.3的第27-32、50-52、89-97位氨基酸所示。
  2. 根据权利要求1所述的单克隆抗体，其特征在于，所述抗体重链的可变区以及轻链的可变区的氨基酸序列分别如SEQ ID NO.1以及SEQ ID NO.3所示。
  3. 根据权利要求2所述的单克隆抗体，其特征在于，所述抗体重链恒定区的氨基酸序列如SEQ ID NO.13所示，所述轻链恒定区的氨基酸序列如SEQ ID NO.15所示。
  4. 一种编码权利要求2或3所述人源化广谱高中和活性抗新型冠状病毒单克隆抗体的多核苷酸，其特征在于，编码所述抗体重链的可变区的多核苷酸以及编码所述抗体轻链的可变区的多核苷酸的序列分别如SEQ ID NO.2以及SEQ ID NO.4所示。
  5. 根据权利要求4所述的编码单克隆抗体的多核苷酸，其特征在于，编码抗体重链恒定区的多核苷酸的序列如SEQ ID NO.14所示，编码所述轻链恒定区的多核苷酸的序列如SEQ ID NO.16所示。
  6. 一种表达权利要求2或3所述人源化高中和活性抗新型冠状病毒单克隆抗体的载体，其特征在于，所述载体含有权利要求4所述编码所述抗体重链的可变区的多核苷酸以及编码所述抗体轻链的可变区的多核苷酸。
  7. 一种表达权利要求2或3所述人源化高中和活性抗新型冠状病毒单克隆抗体的宿主细胞，其特征在于，所述宿主细胞含有权利要求6所述的载体。
  8. 根据权利要求7所述的宿主细胞，其特征在于，所述宿主细胞为293F细胞。
  9. 权利要求1-3任一所述的人源化高中和活性抗新型冠状病毒单克隆抗体在制备新型冠状病毒病治疗和/或预防药物中的应用。
  10. 权利要求1-3任一所述的人源化高中和活性抗新型冠状病毒单克隆抗体在制备新型冠状病毒检测试剂中的应用。
PCT/CN2022/106147 2021-08-01 2022-07-17 人源化高中和活性抗新型冠状病毒单克隆抗体及应用 WO2023011147A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110877644.9 2021-08-01
CN202110877644.9A CN113563464B (zh) 2021-08-01 2021-08-01 人源化高中和活性抗新型冠状病毒单克隆抗体及应用

Publications (1)

Publication Number Publication Date
WO2023011147A1 true WO2023011147A1 (zh) 2023-02-09

Family

ID=78169757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/106147 WO2023011147A1 (zh) 2021-08-01 2022-07-17 人源化高中和活性抗新型冠状病毒单克隆抗体及应用

Country Status (2)

Country Link
CN (1) CN113563464B (zh)
WO (1) WO2023011147A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113563464B (zh) * 2021-08-01 2023-02-03 中国疾病预防控制中心性病艾滋病预防控制中心 人源化高中和活性抗新型冠状病毒单克隆抗体及应用
CN114989292B (zh) * 2021-11-25 2023-01-06 浙江安维珞诊断技术有限公司 一种抗SARS-CoV-2全人源化单克隆抗体及应用
WO2023102692A1 (zh) * 2021-12-06 2023-06-15 广州医科大学附属市八医院 协同中和新型冠状病毒的人源抗体和抗体组合及其应用
CN114805557B (zh) * 2021-12-31 2023-07-21 中国科学院微生物研究所 人源化抗SARS-CoV-2单克隆抗体及其应用
CN114044821B (zh) * 2022-01-10 2022-03-25 中国人民解放军军事科学院军事医学研究院 一种抗新冠病毒全人源广谱中和抗体zwc12及应用
CN114106166B (zh) * 2022-01-29 2022-05-06 中国疾病预防控制中心病毒病预防控制所 人源抗新冠病毒中和性抗体d2及其应用
CN114426577B (zh) * 2022-02-07 2023-10-13 中国疾病预防控制中心性病艾滋病预防控制中心 人源化广谱抗新型冠状病毒单克隆抗体及应用
CN117866084A (zh) * 2022-03-02 2024-04-12 南昌大学 一种抗新型冠状病毒的全人源单克隆抗体及其用途
CN117003859A (zh) * 2022-05-07 2023-11-07 广东菲鹏制药股份有限公司 抗新型冠状病毒人源化纳米抗体及其应用
CN114790240B (zh) * 2022-06-10 2023-06-06 郑州大学 SARS-CoV-2中和性单克隆抗体及应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10822379B1 (en) * 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2
CN111909261A (zh) * 2020-08-19 2020-11-10 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
CN111925443A (zh) * 2020-08-19 2020-11-13 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
CN112159469A (zh) * 2020-09-30 2021-01-01 上海市公共卫生临床中心 冠状病毒的抗体或其抗原结合片段
CN112341541A (zh) * 2020-11-23 2021-02-09 中国疾病预防控制中心病毒病预防控制所 人源抗新冠病毒中和性抗体nCoV-163及其应用
CN112430265A (zh) * 2020-11-23 2021-03-02 中国疾病预防控制中心病毒病预防控制所 人源抗新冠病毒中和性抗体nCoV-61及其应用
CN113563464A (zh) * 2021-08-01 2021-10-29 中国疾病预防控制中心性病艾滋病预防控制中心 人源化高中和活性抗新型冠状病毒单克隆抗体及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3263595A1 (en) * 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
CA3065919A1 (en) * 2017-06-07 2018-12-13 Silverback Therapeutics, Inc. Antibody construct conjugates
CN112794899B (zh) * 2021-03-16 2021-09-24 易康生物(苏州)有限公司 一种抗新型冠状病毒的全人源单克隆中和抗体及其应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10822379B1 (en) * 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2
CN111909261A (zh) * 2020-08-19 2020-11-10 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
CN111925443A (zh) * 2020-08-19 2020-11-13 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
CN112159469A (zh) * 2020-09-30 2021-01-01 上海市公共卫生临床中心 冠状病毒的抗体或其抗原结合片段
CN112341541A (zh) * 2020-11-23 2021-02-09 中国疾病预防控制中心病毒病预防控制所 人源抗新冠病毒中和性抗体nCoV-163及其应用
CN112430265A (zh) * 2020-11-23 2021-03-02 中国疾病预防控制中心病毒病预防控制所 人源抗新冠病毒中和性抗体nCoV-61及其应用
CN113563464A (zh) * 2021-08-01 2021-10-29 中国疾病预防控制中心性病艾滋病预防控制中心 人源化高中和活性抗新型冠状病毒单克隆抗体及应用

Also Published As

Publication number Publication date
CN113563464B (zh) 2023-02-03
CN113563464A (zh) 2021-10-29

Similar Documents

Publication Publication Date Title
CN113563464B (zh) 人源化高中和活性抗新型冠状病毒单克隆抗体及应用
WO2023011167A1 (zh) 人源化广谱高中和活性抗新型冠状病毒单克隆抗体及应用
CN110144010B9 (zh) 阻断型pd-l1驼源单域抗体及其用途
CN101133158B (zh) 人抗狂犬病抗体及其用途
CN113166256A (zh) 一种新型抗c-kit抗体
CN103145849B (zh) 嵌合抗原受体及其用途
DK2708558T3 (en) Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
RU2759846C2 (ru) Дисплей интегрального мембранного белка на внеклеточных оболочечных вирионах поксвируса
CN109796535B (zh) 靶向叶酸受体α的嵌合抗原受体及其在制备预防或治疗恶性肿瘤药物中的用途
KR102260680B1 (ko) 신규 항 인간 tslp 수용체 항체
CN114149509B (zh) 抗冠状病毒双特异性中和抗体与应用
CN114107212A (zh) 细胞
CN111819198A (zh) 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA)
CN116194476A (zh) 针对sars-cov-2的抗体和其使用方法
CN108424461B (zh) Cd47-car-t细胞
CN105384819B (zh) 一种抗人Delta-like 4人源化抗体及其制备与应用
CN114480501B (zh) 一种人源抗体表达质粒及其构建方法
CN107936118B (zh) 一种抗体-海兔毒素偶联物及其制备方法和应用
AU2002332600B2 (en) Recombinant antibodies, and compositions and methods for making and using the same
CN108752472B (zh) 一种抗h7n9抗体及其制备方法和应用
CN106866824B (zh) 一种抗ddx5的全人源单克隆抗体及其制备方法和应用
CN114409774B (zh) 广谱人源化抗新型冠状病毒单克隆抗体及应用
CN114426577B (zh) 人源化广谱抗新型冠状病毒单克隆抗体及应用
AU2021273789A1 (en) Human IL-15 mutant and use thereof
CN114213531B (zh) 抗新型冠状病毒中和抗体、其抗原结合片段及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22851861

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE